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To the Editor: We thank Dr Yardley and Dr Sigal for their
comments on the position statement pertaining to the use of
continuous glucose monitoring (CGM) systems around exercise
in type 1 diabetes [1, 2]. The letter by Yardley and Sigal was
centred on four points: (1) the potential difference in risk of
hypoglycaemia in active vs inactive people; (2) possible sex
differences in exercise-related hypoglycaemia risk; (3) the role
of bolus insulin administration to prevent and/or correct exercise-
related hyperglycaemia that is sometimes associated with high-
intensity interval exercise (HIIE) and/or resistance exercise; and
(4) the role of the prandial state on glucose responses during
exercise.
As Yardley and Sigal state [1], the role of fitness level and/or
exercise experience on the risk for hypoglycaemia during or after
exercise is unclear. To clarify, our position statement did not
mention that ‘inactive’ people with type 1 diabetes have a higher
risk of hypoglycaemia per se; however, it was discussed that
‘individuals who do not routinely exercise may face an increased
risk of hypoglycaemia’, ‘partially’ in line with the study of Bohn
et al [2, 3]. Yardley and Sigal reference the article byAl Khalifah
et al [4] as evidence that people who aremore aerobically fit may
have a higher likelihood of becoming hypoglycaemic during
exercise compared with those less fit. A closer look at the data
from this paper, however, indicates that there was a much larger
number of participants in the ‘good fitness’ group who
performed treadmill exercise (n = 19) compared with exercise
on the stationary bike (n = 4), whereas, in the ‘poor fitness’
group, a larger number of participants performed exercise on
the stationary bike (n = 11) compared with the treadmill (n =
9). A larger percentage of hypoglycaemia occurred across both
groups with the treadmill exercise compared with exercise on the
stationary bike, perhaps partly because the treadmill exercise was
twice as long as that on the stationary bike. For this reason, a
number of confounders prevent a conclusion on the impact of
fitness level on likelihood of hypoglycaemia based on these
results. Based on the large cross-sectional study by Bohn et al
[3] and in agreement with the present writing groups’ clinical
experience, we would still recommend higher glucose levels
during exercise for those that are not routinely exercising to
ensure safe exercise and a low risk of hypoglycaemia.
Importantly, if a person exercises routinely and/or has a low risk
of hypoglycaemia over a period of 3 months, then the glycaemic
thresholds for carbohydrate consumption might be adjusted, as
emphasised in our statement [2].
Thank you for discussing several studies showing how
hypoglycaemia risk during exercise can be different for male
individuals vs female individuals. In Fig. 1 of the manuscript
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by Bohn et al, severe hypoglycaemia was demonstrated to
occur more often in physically active female participants
compared with male participants; however, the difference
was small (two events per 100 person-years) [3]. Brockman
et al [5] showed that it was male individuals, not females, who
experienced the sharper decrease in glucose during resistance
exercise and also higher rates of hypoglycaemia. Given the
conflicting results, small differences between the groups and
the limited studies in this area, we provided an initial focus on
the overall population of people with type 1 diabetes, separat-
ing them into adults, adolescents and children, with subgroups
based on risk of hypoglycaemia [2]. While we anticipate that
future studies will provide a more complete picture on the role
of sex in modulating exercise-induced changes in blood
glucose levels, our position statement [2] is a first step towards
evidence-based general recommendations about how to use
CGM systems around exercise.
The authors mention in their letter that we recommend a
bolus insulin correction in advance of HIIE and resistance
exercise. While dosing insulin in advance of HIIE and resis-
tance exercise may be dangerous in some situations, for the
points raised in our position statement [2], we recommended a
50% reduced correction factor of the regular insulin dose at
glucose levels >10 mmol/l, and not an insulin correction dose
before HIIE and resistance exercise in general (see Table 1 in
the position statement [2]). We also note that pre-exercise
extreme hyperglycaemia (sensor glucose levels >15 mmol/l)
can be treated with an insulin bolus (50% of a typical correc-
tion dose) [2]. We maintain this recommendation, given the
strong emphasis for the use of CGM in this position statement
to allow for the safe monitoring of glucose levels post insulin
correction [2]. We feel that it is unwarranted to recommend
that people with type 1 diabetes ignore their pre-exercise
hyperglycaemia prior to exercise or competition [6].
We agree with Yardley and Sigal that a determining factor
of whether glucose increases during resistance exercise or
HIIE may be dependent on the prandial state [1]. We agree
that wemay expect to see elevated glucose levels during resis-
tance exercise and HIIE when done in the fasted state and
addressed this point in the position statement, where we stated
that ‘if sensor glucose is expected to increase, as often seen in
people performing fasted high-intensity interval training,
resistance training and, also, in training above the anaerobic
threshold, then an insulin correction can be administered at the
onset of, as well as during exercise (50% of typical correction
factor)’ [2].
The four points discussed here highlight the multiple
factors involved in intra- and interindividual glucose
response to physical activity and exercise in individuals
living with type 1 diabetes and, accordingly, the difficulties
encountered by them in anticipating and managing glucose
in these situations. Thus, we would like to thank the authors
for their support on this position statement and appreciate
the additional viewpoints that will be considered in future
updates of a rapidly advancing area.
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